Stocks Health care PGEN
NASDAQ · Health carePrecigen, Inc. (PGEN)
Precigen, Inc. brought in $156.9M of revenue over the twelve months to September 30, 2026. Net income was $24.4M, a net margin of 15.6%. In fiscal 2025 capital spending exceeded operating cash flow by $89.8M. At September 30, 2026 it held $15M in cash against $94.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Precigen, Inc.
- Net worth
- Precigen, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $83.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $9.7M (+146.7% year on year), with a net loss of $250.6M. Over the 12 months to September 30, 2026: revenue $156.9M, net income $24.4M.
- Cash flow
- In fiscal 2025 operations used $87.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Precigen, Inc.'s next report is expected around March 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Precigen, Inc. does
Precigen, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PGEN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $9.7M | -$250.6M | -$1.37 | -$89.8M |
| 2024 | $3.9M | -$126.2M | -$0.47 | -$76.8M |
| 2023 | $6.2M | -$95.9M | -$0.39 | -$68.5M |
| 2022 | $26.9M | $28.3M | $0.14 | -$70M |
| 2021 | $14.3M | -$92.2M | -$0.47 | -$63M |
| 2020 | $32M | -$170.5M | -$1.02 | -$84.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PGEN ranks in Health care
Latest SEC filings
What Precigen, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 2,438% to $74.1M versus the same quarter last year; diluted EPS $0.08 versus -$1.06.
- August 7, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 6,323% to $55M versus the same quarter last year; diluted EPS $0.05 versus -$0.09.
- August 4, 2026
- June 24, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 1,634% to $23.3M versus the same quarter last year; diluted EPS -$0.02 versus -$0.18.
- April 30, 2026
Insider trades
What the people running Precigen, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $24.7K and sold $2.3M worth of shares in the last 90 days. 41% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 23, 2026 | Thomasian Harry Jr.Chief Financial Officer | Exercised options | 10,744 | $50.7K |
| September 23, 2026 | Thomasian Harry Jr.Chief Financial Officer | Exercised options | 42,918 | $100K |
| September 23, 2026 | Thomasian Harry Jr.Chief Financial Officer | Exercised options | 2 | $1.9 |
| September 23, 2026 | Thomasian Harry Jr.Chief Financial Officer | Exercised options | 1 | $1.2 |
| August 26, 2026 | Kindler Jeffrey BDirector | Sold | 185,000 | $1.4M |
| August 25, 2026 | Tennant PhilChief Commercial Officer | Exercised options | 79,166 | $127.5K |
| August 25, 2026 | Tennant PhilChief Commercial Officer | Soldpre-planned (10b5-1) | 79,166 | $593.7K |
| August 25, 2026 | Shah Rutul RChief Operating Officer | Exercised options | 15,342 | $35.7K |
Who owns PGEN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Randal J. Kirk13D, may seek influence with 2 related filers | 35.9% | March 31, 2026 |
| Patient Capital Management, LLC13G, passive with 1 related filers | 10.2% | February 13, 2026 |
| William H. Miller III Living Trust dated April 17, 201713G, passive | 9.2% | September 23, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 211 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Patient Capital Management, LLC | 19,036,976 | +1,219,589 |
| BlackRock, Inc. | 17,146,921 | +1,923,730 |
| State Street Corp | 12,002,465 | +1,112,341 |
| Diametric Capital, LP | 9,269,926 | +2,468,138 |
| Vanguard Capital Management LLC | 7,906,160 | +757,164 |
| Tang Capital Management LLC | 6,417,500 | 0 |
| Boxer Capital Management, LLC | 5,150,000 | +1,650,000 |
| Geode Capital Management, LLC | 5,019,028 | +405,599 |
| Iridian Asset Management LLC | 4,031,963 | +439,233 |
| Morgan Stanley | 3,469,628 | +1,055,306 |
| Occam Crest Management LP | 3,605,941 | -663,110 |
| Goldman Sachs Group Inc | 3,406,456 | +55,979 |
| Fmr LLC | 2,570,183 | +571,587 |
| Vanguard Portfolio Management LLC | 2,211,172 | +95,161 |
| First Trust Advisors LP | 2,014,659 | new |
| Bank of America Corp | 1,848,414 | +377,135 |
| Arrowstreet Capital, Limited Partnership | 1,788,235 | +1,392,540 |
| Northern Trust Corp | 1,779,380 | +167,590 |
| Charles Schwab Investment Management Inc | 1,515,853 | +55,233 |
| Woodline Partners LP | 1,401,945 | +533 |
Insiders
13 insiders reported holding 22,653,484 shares in total, about $100.7M at the last price.
| Holder | Shares |
|---|---|
| Kirk Randal JDirector, 10% owner | 12,262,74112,262,741 held indirectly |
| Sabzevari HelenPresident and CEO | 3,779,521 |
| Hassan FredDirector | 1,243,239 |
| Frank StevenDirector | 1,226,391 |
| Alvarez Cesar LDirector | 782,909 |
| Lehr Donald P.Chief Legal Officer | 758,181 |
| Turley James SDirector | 685,417 |
| Gupta Vinita DDirector | 666,027 |
| Shah Rutul RChief Operating Officer | 468,865 |
| Thomasian Harry Jr.Chief Financial Officer | 311,914 |
Questions about PGEN
What does Precigen, Inc. do?
Precigen, Inc. is a company in the Health care sector, listed on NASDAQ as PGEN. Its shares trade on NASDAQ under the ticker PGEN.
What is Precigen, Inc.'s net worth?
Precigen, Inc. has a market value (market cap) of $1.6B at the latest share price, and shareholders' equity of $83.8M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Precigen, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $24.4M on revenue of $156.9M, a net margin of 15.6%.
How much revenue does Precigen, Inc. make?
Over the twelve months to September 30, 2026 Precigen, Inc. reported revenue of $156.9M.
When did Precigen, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the quarterly results from November 5, 2026.
When is Precigen, Inc.'s next earnings report?
Precigen, Inc.'s next report is expected around March 24, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PGEN with
Follow PGEN
Get an email when Precigen, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Precigen, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.